Prof. Saber Imani | Mpox | Best Researcher Award

Prof. Saber Imani, Zhejiang Shuren University, China.

Prof. Saber Imani is an accomplished researcher and educator in oncology, with expertise in cancer immunology, epigenetics, and therapeutic technologies. He holds an Assistant Professorship at Zhejiang Shuren University, China, and has a distinguished career spanning institutions in Iran, China, and the USA. Prof. Imani’s research focuses on innovative cancer therapies, including mRNA vaccines and nano-cancer treatments, and he has published over 110 scientific papers with significant citations. His mentorship and active involvement in global oncology organizations underscore his leadership in advancing cancer research.

Professional Profile

Scopus Profile

📚Education

Prof. Saber Imani holds a Ph.D. in Molecular Medicine from Baqiyatallah University of Medical Sciences, Tehran, Iran (2011-2015), awarded on 20/11/2015. He completed his Master of Science in Cellular and Molecular Biology at the Department of Biology, College of Science, IHU, Tehran, Iran (2009-2011), with the degree awarded on 01/09/2011. Prior to that, he earned his Bachelor of Science in Microbiology from the Department of Biology, College of Science, IHU, Tehran, Iran (2005-2009), graduating on 21/07/2009. He also attended Junior High School and High School with a major in Sciences (2001-2005).

💼Experience

Prof. Saber Imani has extensive professional experience in the field of oncology and genomics. He served as an Assistant Professor of Translational Oncology at the Department of Oncology, The Affiliated Hospital of Southwest Medical University in Sichuan, P.R. China, from 2020 to 2022. Prior to that, he was a Postdoctoral Fellow of Translational Genomics at the Pediatrics Department, Washington University School of Medicine, St. Louis, MO, USA, from 2019 to 2020. Additionally, he worked as a Postdoctoral Fellow of Cancer Epigenetics at the Key Laboratory of Epigenetics, Zhejiang University, Hangzhou, P.R. China, from 2015 to 2018, with his award date being 10/05/2018.

🔬Research Interest

Prof. Saber Imani’s research interests focus on several cutting-edge areas in cancer treatment and genomics. His work includes the development of mRNA cancer vaccines, translational immune-oncology, and genomics oncology. He is also deeply engaged in cancer epigenetics and exploring innovative approaches like nano cancer therapy to improve cancer treatment outcomes. These areas of research reflect his commitment to advancing the understanding and treatment of cancer through novel, targeted therapeutic strategies.

🧠Skills

Prof. Saber Imani possesses a diverse and comprehensive skill set across languages, laboratory techniques, bioinformatics, and computer software. He is proficient in English, Turkish (native), Persian, and is currently learning Chinese. In the laboratory, he is skilled in extractions (DNA, protein, polymers, cell extracts), various types of PCR (including Reverse Transcriptase, Real-Time, and LAMP), and immunology techniques such as blood typing and antigen-antibody interactions. He has extensive experience in cell screening (mesenchymal cells, bacterial cells, enzymes), cell culture (mesenchymal, plant, bacterial cells), and cloning (bacterial and animal cells). Prof. Imani is also proficient in flow cytometry, primer design (using tools like Oligo 6 and Generunner), and sequence alignment with platforms such as CLC workbench, BLAST, and GeneDock. His expertise extends to bioinformatics (including homology-based modeling, dynamics modeling, and alignment) and next-generation sequencing using Illumina MiSeq services. On the computer front, he is highly skilled in Microsoft Office, Adobe Photoshop, and scientific tools such as SPSS, Flowjo, AutoDock, MiSeq Control Software (MCS), and GROMCS V 4.5.5.

🎖️Honors and Achievements

Prof. Saber Imani has achieved numerous prestigious honors throughout his academic and professional career. In 2019, he was appointed Ambassador of the European Association for Cancer Research (EACR) in Sichuan Province, China. He also received the Sichuan Province Medical Science and Technology Award in 2018. As a leading expert in his field, Prof. Imani is an active member of top organizations such as the European Society for Medical Oncology (ESMO) and the American Association for Cancer Research (AACR). His academic excellence is demonstrated by his receipt of the Ph.D. Scholarship from the CAS-TWAS President’s Fellowship Program in 2015. Prof. Imani’s academic journey also includes being named The Nation’s Top Student in Biology in Iran (2011-2012) and securing the 1st rank among 20 graduates in his Master’s program, as well as the 2nd rank among 45 graduates in his Bachelor’s program. He also earned 3rd place in the International Technology, Invention of West Asia (ITI) competition (2010-2011). His scholarly impact is reflected in his Saber Statistics, which include 112 ISC papers, an impressive mean impact factor of 8.23, 2,141 citations, and an h-index of 27.

🎙️Teaching sessions

Prof. Saber Imani’s teaching activities include a range of courses aimed at providing students and scientists with crucial knowledge and practical skills. The “Targeted Cancer Therapy” course explores the key concepts of precision oncology, guiding students through topics such as genomic analysis, cancer biomarkers, risk assessment of chronic diseases, and gene-environment interactions, while bridging the gap from bench to bedside and population health. The “Cancer Epigenetics Course” complements this by offering in-depth exploration of epigenetic mechanisms in cancer, with additional resources from Prof. Imani’s e-book, “Epigenetics in Cancer” (Alpha Science Inter. Pub., Oxford, UK & Science Press, Beijing, China). Finally, the “Scientific Writing Course” helps students and scientists improve their writing skills by covering essential topics like scientific manuscript preparation, grant writing, pre-review, and ethical issues in scientific publication, with practical exercises aimed at reducing writing anxiety and enhancing clarity for both scientific and general audiences.

📑Top Note Publications

Title: Exploration of drug repurposing for Mpox outbreaks targeting gene signatures and host-pathogen interactions

Authors: Imani, S., Aminnezhad, S., Alikarami, M., Maghsoudloo, M., Taheri, Z.
Publication Year: 2024
Citations: 0

Title: Neoantigen vaccine nanoformulations based on Chemically synthesized minimal mRNA (CmRNA): small molecules, big impact

Authors: Imani, S., Tagit, O., Pichon, C.
Publication Year: 2024
Citations: 5

Title: Comprehensive assessment of TECENTRIQ® and OPDIVO®: analyzing immunotherapy indications withdrawn in triple-negative breast cancer and hepatocellular carcinom

Authors: Roozitalab, G., Abedi, B., Imani, S., Farghadani, R., Jabbarzadeh Kaboli, P.
Publication Year: 2024
Citations: 3

Title: Navigating ESKAPE Pathogens: Considerations and Caveats for Animal Infection Models Development

Authors: Yu, H., Xu, Y., Imani, S., Ullah, S., Wang, Q.
Publication Year: 2024
Citations: 1

Title: The evolution of BRAF-targeted therapies in melanoma: overcoming hurdles and unleashing novel strategies

Authors: Imani, S., Roozitalab, G., Emadi, M., Behzadi, P., Jabbarzadeh Kaboli, P.
Publication Year: 2024
Citations: 0